- Phase 2 STORYLINE trial for ABS-201 (anti-PRLR antibody) in endometriosis is planned.
- Double-blind, randomized, placebo-controlled design.
- Approximately 150 patients with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain.
- Multi-center trial across 10+ countries.
- Primary endpoints: dysmenorrhea and non-menstrual pelvic pain.
- Trial initiation expected in mid-2027, pending regulatory clearance and final protocol.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card